email   Email Us: phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

  Submit Manuscript

ISSN: 2637-4706

Drug Designing & Intellectual Properties International Journal

Opinion(ISSN: 2637-4706)

Bioequivalent Drugs: Towards A Needed Holistic Paradigm Shift?

Volume 2 - Issue 4

François-Xavier Lacasse*

  • Author Information Open or Close
    • Faculty of Pharmacy, University of Montreal, Canada

    *Corresponding author: François-Xavier Lacasse, Faculty of Pharmacy, University of Montreal, Canada

Received:October 17, 2018;   Published: October 24, 2018

DOI: 10.32474/DDIPIJ.2018.02.000144

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF


The author of this short communication has been working in and teaching drug development for the last 20 years. He has been involved in more than 100 drug development projects, including drug delivery, medical device, biologics, innovators and generic drugs. He has also been involved in all the steps that are needed to file properly to different governmental agencies investigational new drug applications (IND), clinical trial applications (CTA), abbreviated and new drug applications/submissions (ANDA\S; NDA/S), 505b2, 510k and biologics legal applications (BLA). After several other interactions with all the other actors, such as Health Canada (HC), the Food and Drug Agency (FDA), the European Medicines Agency (EMA), pharmacovigilance companies and consultants, public relation companies, insurance companies and especially patients, the author has decided to gather all the comments in order to initiate a kind of a new debate on the innovators and generic drugs. However, the goal of this current expert opinion is not to generate conflicts, or to compare generic versus innovator drugs in the sense that one is better than the other. The author has already been involved in several bioequivalence studies, comparing two innovator products where the results showed lack of bioequivalence….or in bioequivalence studies evaluated with clinical endpoint where generic drug products were more potent than the innovators…The goal of this paper should be more based on the following question: are the current methods used to assess bioequivalence are suitable and reliable enough to “stamp” that generic drugs are bioequivalent, are as stable, reliable form a quality, a safety and efficacy standpoints.

Opinion| Bioequivalence…. What Does It Mean?| So…Finally Can Generic Drugs Be Considered on the Same Footing Than Innovators?| Refernces|


Online Submission System

Drag and drop files here


Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )